Global and U.S. Pharmaceutical Business Leader with extensive strategic marketing and marketing operations experience across a range of pharma and biopharma products. Demonstrated ability to inspire and lead commercial and cross-functional teams with a “hands-on” approach developed over a diversified 20+ years in the industry. Proven record of exceeding expectations in successfully launching and marketing new and in-line products in the U.S. and international markets. Innovative marketer demonstrating success in developing and executing unique strategies and tactics targeting specialty, primary care, and payer audiences. Distinct skill set in ability to deeply and personally connect with customers, HCPs, patients, payers, advocacy groups, external partners, and internal colleagues.

Team Leader, US Marketing @ • U.S. Commercial Lead for Vyndaqel. Responsible for marketing team and cross-functional team for NDA defense strategy. • Developed a market where one previously did not exist for an ultra rare orphan disease relying on extensive best practices research to develop a strategic and unique zero-based approach. • Obtained organizational buy-in for a non-traditional approach in creating a focused and dedicated marketing, sales, and extended operational team poised for a successful launch. • Developed and obtained executive level organizational buy-in for multiple regulatory scenarios and contingencies. • Forged deep relationships with key HCPs (OLs), Patient Support Groups, and other stakeholders where none had previously existed. • Developed and gained approval for HCP and Consumer pre-launch and launch plans tied to business objectives. Pre-Launch plans executed successfully and within budget. • Extensive commercial contribution to the VYNDAQEL FDA Advisory Committee plan. • Overall, took personal accountability for leading organization's move to one of clear leadership and partnership. From January 2010 to Present (6 years) Assistant Vice President, US Marketing @ • Led 2008 U.S. launch of RELISTOR (Opioid Induced Constipation) and associated marketing strategies and tactics. Developed sales and marketing strategy, launch campaign, and launch plan for partnered compound. Led experienced group of HCP, Consumer, and Payer marketers in implementation of launch plan across 5 sales forces and 2000+ sales representatives. Developed extensive innovative approach to change entrenched behaviors of HCPs and essentially create a new market. Deployed JSC structure and transitioned product flawlessly to partner company. • Responsible for pre-launch commercial development of APRELA (Post Menopausal Vasomotor Symptoms) and associated marketing strategy and tactics for U.S. Provided commercial leadership for development plan, regulatory plan, supply plan, and intellectual property plan. From 2007 to 2010 (3 years) Executive Director, Worldwide Marketing @ • Led U.S. marketing for BeneFIX (Hemophilia B). Changed sales trajectory from flat to 15%+ growth by applying innovative, grass-roots marketing strategies and tactics. • Responsible for European Launch of BeneFIX. Led flawless transfer of marketing/distribution rights from multiple Baxter entities to 16 Wyeth Affiliates. • Globally launched BeneFIX reformulation and new device (U.S. and International). Maximized impact while minimizing sales (supply) interruptions. From 2005 to 2007 (2 years) Senior Director, Global Marketing @ • Repositioned ReFacto (Hemophilia A) including the development of an award winning HCP advertising campaign. Campaign developed with collaboration across worldwide Wyeth Affiliates resulting in every Affiliate adopting the global campaign; all markets adhered to consistent creative and messaging in line with global strategy and positioning. Efforts resulted in worldwide product growth of approximately 20% per year with a relatively clinically undifferentiated product. Successful worldwide Affiliate Leadership tactics changed paradigm for International Marketing (Affiliate/Home Office Interaction) at Wyeth. • Responsible for commercial development of next generation rFVIII (XYNTHA in U.S. and ReFacto AF in E.U.). Product approved and launched (2008). • Responsible for Worldwide Launch of recalibrated ReFacto and enhanced delivery device (R2). • Contributed to Profit Improvement Plan via in depth analyses for worldwide hemophilia business. From 2003 to 2005 (2 years)

Master of Business Administration (MBA), Pharmaceutical Marketing and Management @ Saint Joseph's University From 1994 to 1999 Bachelor's of Chemical Engineering, Chemical Engineering @ University of Delaware From 1986 to 1990 Dan Levin is skilled in: Cross-functional Team Leadership, Marketing, Pharmaceutics, Biotechnology, Leadership, Marketing Strategy, Budgets, Global Marketing, Strategy, Biopharmaceuticals, Product Launch, Pharmaceutical Industry, Sales Effectiveness, FDA, Analysis